Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial
Potassium depletion by thiazide diuretics is associated with a rise in blood glucose. We assessed whether addition or substitution of a potassium-sparing diuretic, amiloride, to treatment with a thiazide can prevent glucose intolerance and improve blood pressure control. We did a parallel-group, ran...
Uložené v:
| Vydané v: | The lancet. Diabetes & endocrinology Ročník 4; číslo 2; s. 136 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
01.02.2016
|
| Predmet: | |
| ISSN: | 2213-8595, 2213-8595 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Potassium depletion by thiazide diuretics is associated with a rise in blood glucose. We assessed whether addition or substitution of a potassium-sparing diuretic, amiloride, to treatment with a thiazide can prevent glucose intolerance and improve blood pressure control.
We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care sites in the UK. Eligible patients were aged 18-80 years; had clinic systolic blood pressure of 140 mm Hg or higher and home systolic blood pressure of 130 mmHg or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, β blockers, calcium-channel blockers, or direct renin inhibitors (previously untreated patients were also eligible in specific circumstances); and had at least one component of the metabolic syndrome in addition to hypertension. Patients with known diabetes were excluded. Patients were randomly assigned (1:1:1) to 24 weeks of daily oral treatment with starting doses of 10 mg amiloride, 25 mg hydrochlorothiazide, or 5 mg amiloride plus 12·5 mg hydrochlorothiazide; all doses were doubled after 12 weeks. Random assignment was done via a central computer system. Both participants and investigators were masked to assignment. Our hierarchical primary endpoints, assessed on a modified intention-to-treat basis at 12 and 24 weeks, were the differences from baseline in blood glucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydrochlorothiazide and amiloride groups, and then between the hydrochlorothiazide and combination groups. A key secondary endpoint was change in home systolic blood pressure at 12 and 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862, and the MHRA, Eudract number 2009-010068-41, and is now complete.
Between Nov 18, 2009, and Dec 15, 2014, 145 patients were randomly assigned to amiloride, 146 to hydrochlorothiazide, and 150 to the combination group. 132 participants in the amiloride group, 134 in the hydrochlorothiazide group, and 133 in the combination group were included in the modified intention-to-treat analysis. 2 h glucose concentrations after OGTT, averaged at 12 and 24 weeks, were significantly lower in the amiloride group than in the hydrochlorothiazide group (mean difference -0·55 mmol/L [95% CI -0·96 to -0·14]; p=0·0093) and in the combination group than in the hydrochlorothiazide group (-0·42 mmol/L [-0·84 to -0·004]; p=0·048). The mean reduction in home systolic blood pressure during 24 weeks did not differ significantly between the amiloride and hydrochlorothiazide groups, but the fall in blood pressure in the combination group was significantly greater than that in the hydrochlorothiazide group (p=0·0068). Hyperkalaemia was reported in seven (4·8%) patients in the amiloride group and three (2·3%) patients in the combination group; the highest recorded potassium concentration was 5·8 mmol/L in a patient in the amiloride group. 13 serious adverse events occurred but the frequency did not differ significantly between groups.
The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressure, prevents glucose intolerance and improves control of blood pressure compared with montherapy with either drug. These findings, together with previous data about morbidity and mortality for the combination, support first-line use of amiloride plus hydrochlorothiazide in hypertensive patients who need treatment with a diuretic.
British Heart Foundation and National Institute for Health Research. |
|---|---|
| AbstractList | Potassium depletion by thiazide diuretics is associated with a rise in blood glucose. We assessed whether addition or substitution of a potassium-sparing diuretic, amiloride, to treatment with a thiazide can prevent glucose intolerance and improve blood pressure control.
We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care sites in the UK. Eligible patients were aged 18-80 years; had clinic systolic blood pressure of 140 mm Hg or higher and home systolic blood pressure of 130 mmHg or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, β blockers, calcium-channel blockers, or direct renin inhibitors (previously untreated patients were also eligible in specific circumstances); and had at least one component of the metabolic syndrome in addition to hypertension. Patients with known diabetes were excluded. Patients were randomly assigned (1:1:1) to 24 weeks of daily oral treatment with starting doses of 10 mg amiloride, 25 mg hydrochlorothiazide, or 5 mg amiloride plus 12·5 mg hydrochlorothiazide; all doses were doubled after 12 weeks. Random assignment was done via a central computer system. Both participants and investigators were masked to assignment. Our hierarchical primary endpoints, assessed on a modified intention-to-treat basis at 12 and 24 weeks, were the differences from baseline in blood glucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydrochlorothiazide and amiloride groups, and then between the hydrochlorothiazide and combination groups. A key secondary endpoint was change in home systolic blood pressure at 12 and 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862, and the MHRA, Eudract number 2009-010068-41, and is now complete.
Between Nov 18, 2009, and Dec 15, 2014, 145 patients were randomly assigned to amiloride, 146 to hydrochlorothiazide, and 150 to the combination group. 132 participants in the amiloride group, 134 in the hydrochlorothiazide group, and 133 in the combination group were included in the modified intention-to-treat analysis. 2 h glucose concentrations after OGTT, averaged at 12 and 24 weeks, were significantly lower in the amiloride group than in the hydrochlorothiazide group (mean difference -0·55 mmol/L [95% CI -0·96 to -0·14]; p=0·0093) and in the combination group than in the hydrochlorothiazide group (-0·42 mmol/L [-0·84 to -0·004]; p=0·048). The mean reduction in home systolic blood pressure during 24 weeks did not differ significantly between the amiloride and hydrochlorothiazide groups, but the fall in blood pressure in the combination group was significantly greater than that in the hydrochlorothiazide group (p=0·0068). Hyperkalaemia was reported in seven (4·8%) patients in the amiloride group and three (2·3%) patients in the combination group; the highest recorded potassium concentration was 5·8 mmol/L in a patient in the amiloride group. 13 serious adverse events occurred but the frequency did not differ significantly between groups.
The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressure, prevents glucose intolerance and improves control of blood pressure compared with montherapy with either drug. These findings, together with previous data about morbidity and mortality for the combination, support first-line use of amiloride plus hydrochlorothiazide in hypertensive patients who need treatment with a diuretic.
British Heart Foundation and National Institute for Health Research. Potassium depletion by thiazide diuretics is associated with a rise in blood glucose. We assessed whether addition or substitution of a potassium-sparing diuretic, amiloride, to treatment with a thiazide can prevent glucose intolerance and improve blood pressure control.BACKGROUNDPotassium depletion by thiazide diuretics is associated with a rise in blood glucose. We assessed whether addition or substitution of a potassium-sparing diuretic, amiloride, to treatment with a thiazide can prevent glucose intolerance and improve blood pressure control.We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care sites in the UK. Eligible patients were aged 18-80 years; had clinic systolic blood pressure of 140 mm Hg or higher and home systolic blood pressure of 130 mmHg or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, β blockers, calcium-channel blockers, or direct renin inhibitors (previously untreated patients were also eligible in specific circumstances); and had at least one component of the metabolic syndrome in addition to hypertension. Patients with known diabetes were excluded. Patients were randomly assigned (1:1:1) to 24 weeks of daily oral treatment with starting doses of 10 mg amiloride, 25 mg hydrochlorothiazide, or 5 mg amiloride plus 12·5 mg hydrochlorothiazide; all doses were doubled after 12 weeks. Random assignment was done via a central computer system. Both participants and investigators were masked to assignment. Our hierarchical primary endpoints, assessed on a modified intention-to-treat basis at 12 and 24 weeks, were the differences from baseline in blood glucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydrochlorothiazide and amiloride groups, and then between the hydrochlorothiazide and combination groups. A key secondary endpoint was change in home systolic blood pressure at 12 and 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862, and the MHRA, Eudract number 2009-010068-41, and is now complete.METHODSWe did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care sites in the UK. Eligible patients were aged 18-80 years; had clinic systolic blood pressure of 140 mm Hg or higher and home systolic blood pressure of 130 mmHg or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, β blockers, calcium-channel blockers, or direct renin inhibitors (previously untreated patients were also eligible in specific circumstances); and had at least one component of the metabolic syndrome in addition to hypertension. Patients with known diabetes were excluded. Patients were randomly assigned (1:1:1) to 24 weeks of daily oral treatment with starting doses of 10 mg amiloride, 25 mg hydrochlorothiazide, or 5 mg amiloride plus 12·5 mg hydrochlorothiazide; all doses were doubled after 12 weeks. Random assignment was done via a central computer system. Both participants and investigators were masked to assignment. Our hierarchical primary endpoints, assessed on a modified intention-to-treat basis at 12 and 24 weeks, were the differences from baseline in blood glucose measured 2 h after a 75 g oral glucose tolerance test (OGTT), compared first between the hydrochlorothiazide and amiloride groups, and then between the hydrochlorothiazide and combination groups. A key secondary endpoint was change in home systolic blood pressure at 12 and 24 weeks. This trial is registered with ClinicalTrials.gov, number NCT00797862, and the MHRA, Eudract number 2009-010068-41, and is now complete.Between Nov 18, 2009, and Dec 15, 2014, 145 patients were randomly assigned to amiloride, 146 to hydrochlorothiazide, and 150 to the combination group. 132 participants in the amiloride group, 134 in the hydrochlorothiazide group, and 133 in the combination group were included in the modified intention-to-treat analysis. 2 h glucose concentrations after OGTT, averaged at 12 and 24 weeks, were significantly lower in the amiloride group than in the hydrochlorothiazide group (mean difference -0·55 mmol/L [95% CI -0·96 to -0·14]; p=0·0093) and in the combination group than in the hydrochlorothiazide group (-0·42 mmol/L [-0·84 to -0·004]; p=0·048). The mean reduction in home systolic blood pressure during 24 weeks did not differ significantly between the amiloride and hydrochlorothiazide groups, but the fall in blood pressure in the combination group was significantly greater than that in the hydrochlorothiazide group (p=0·0068). Hyperkalaemia was reported in seven (4·8%) patients in the amiloride group and three (2·3%) patients in the combination group; the highest recorded potassium concentration was 5·8 mmol/L in a patient in the amiloride group. 13 serious adverse events occurred but the frequency did not differ significantly between groups.FINDINGSBetween Nov 18, 2009, and Dec 15, 2014, 145 patients were randomly assigned to amiloride, 146 to hydrochlorothiazide, and 150 to the combination group. 132 participants in the amiloride group, 134 in the hydrochlorothiazide group, and 133 in the combination group were included in the modified intention-to-treat analysis. 2 h glucose concentrations after OGTT, averaged at 12 and 24 weeks, were significantly lower in the amiloride group than in the hydrochlorothiazide group (mean difference -0·55 mmol/L [95% CI -0·96 to -0·14]; p=0·0093) and in the combination group than in the hydrochlorothiazide group (-0·42 mmol/L [-0·84 to -0·004]; p=0·048). The mean reduction in home systolic blood pressure during 24 weeks did not differ significantly between the amiloride and hydrochlorothiazide groups, but the fall in blood pressure in the combination group was significantly greater than that in the hydrochlorothiazide group (p=0·0068). Hyperkalaemia was reported in seven (4·8%) patients in the amiloride group and three (2·3%) patients in the combination group; the highest recorded potassium concentration was 5·8 mmol/L in a patient in the amiloride group. 13 serious adverse events occurred but the frequency did not differ significantly between groups.The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressure, prevents glucose intolerance and improves control of blood pressure compared with montherapy with either drug. These findings, together with previous data about morbidity and mortality for the combination, support first-line use of amiloride plus hydrochlorothiazide in hypertensive patients who need treatment with a diuretic.INTERPRETATIONThe combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressure, prevents glucose intolerance and improves control of blood pressure compared with montherapy with either drug. These findings, together with previous data about morbidity and mortality for the combination, support first-line use of amiloride plus hydrochlorothiazide in hypertensive patients who need treatment with a diuretic.British Heart Foundation and National Institute for Health Research.FUNDINGBritish Heart Foundation and National Institute for Health Research. |
| Author | Cruickshank, J Kennedy Williams, Bryan McInnes, Gordon Salsbury, Jackie MacDonald, Thomas M Sever, Peter Webb, David J Caulfield, Mark J Mackenzie, Isla S Ford, Ian Brown, Morris J Morant, Steve V Padmanabhan, Sandosh |
| Author_xml | – sequence: 1 givenname: Morris J surname: Brown fullname: Brown, Morris J email: m.j.brown@cai.cam.ac.uk organization: Clinical Pharmacology Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK. Electronic address: m.j.brown@cai.cam.ac.uk – sequence: 2 givenname: Bryan surname: Williams fullname: Williams, Bryan organization: Institute of Cardiovascular Sciences, University College London, London, UK; National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK – sequence: 3 givenname: Steve V surname: Morant fullname: Morant, Steve V organization: Medicines Monitoring Unit, Medical Research Institute, University of Dundee, Dundee, Scotland, UK – sequence: 4 givenname: David J surname: Webb fullname: Webb, David J organization: Clinical Pharmacology Unit, University of Edinburgh, Centre for Cardiovascular Science, Queen's Medical Research Institute, Edinburgh, Scotland, UK – sequence: 5 givenname: Mark J surname: Caulfield fullname: Caulfield, Mark J organization: William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK – sequence: 6 givenname: J Kennedy surname: Cruickshank fullname: Cruickshank, J Kennedy organization: Cardiovascular Medicine & Diabetes, King's College London, London, UK – sequence: 7 givenname: Ian surname: Ford fullname: Ford, Ian organization: Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland, UK – sequence: 8 givenname: Gordon surname: McInnes fullname: McInnes, Gordon organization: BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, UK – sequence: 9 givenname: Peter surname: Sever fullname: Sever, Peter organization: International Centre for Circulatory Health, Imperial College London, London, UK – sequence: 10 givenname: Jackie surname: Salsbury fullname: Salsbury, Jackie organization: Clinical Pharmacology Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK – sequence: 11 givenname: Isla S surname: Mackenzie fullname: Mackenzie, Isla S organization: Medicines Monitoring Unit, Medical Research Institute, University of Dundee, Dundee, Scotland, UK – sequence: 12 givenname: Sandosh surname: Padmanabhan fullname: Padmanabhan, Sandosh organization: BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, UK – sequence: 13 givenname: Thomas M surname: MacDonald fullname: MacDonald, Thomas M organization: Medicines Monitoring Unit, Medical Research Institute, University of Dundee, Dundee, Scotland, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26489809$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkN1KAzEQhYNUtP48gpLLFlxNstlk410p1QqCghXxqmSTWbuSbtZkV9DX88VctKIXXs3MmXM-htlDg9rXgNARJaeUUHF2xxhNkzzL5YhmY0JSKROyhYYbWWWDP_0uOozxmRBCSZaKnOygXSZ4rnKihuhjVpZgWuxLrNeV86GycIJ9-J1w47qIV282eLPqJd-uKv3-ZXuFEP_fYV_jJ9cZHwG33kHQtQGsa4sL573FTYAYuwB4dDtZzB8mj0k6PscaNzpo58AlT8F3zQm2viscJIWr-mgPsX5dRejzK92TOW5Dpd0B2i61i3C4qfvo_mK2mM6T65vLq-nkOjGCizZhPLNUWiEVBeCQ8bQgSlgNjClBM0NkyrminAJXkGpjrTQFkwbKTOkcONtHo29uE_xLB7Fd9scYcE7X4Lu4pFJQLqlSqrceb6xdsQa7bEK11uFt-fN49gnszowc |
| CitedBy_id | crossref_primary_10_1161_HYPERTENSIONAHA_125_24871 crossref_primary_10_1186_s13063_019_3909_z crossref_primary_10_1007_s00508_019_01565_0 crossref_primary_10_1007_s00392_017_1095_0 crossref_primary_10_1111_bcp_14109 crossref_primary_10_1161_HYPERTENSIONAHA_120_15026 crossref_primary_10_1097_HJH_0000000000001940 crossref_primary_10_3389_fphys_2018_01868 crossref_primary_10_1001_jama_2024_18080 crossref_primary_10_1007_s10008_020_04559_5 crossref_primary_10_15829_1560_4071_2024_6074 crossref_primary_10_3390_biomedicines12030569 crossref_primary_10_1186_s13643_022_01890_y crossref_primary_10_1007_s40119_016_0063_5 crossref_primary_10_15829_1560_4071_2020_3_3786 crossref_primary_10_1038_s41440_020_0428_y crossref_primary_10_1002_pds_4636 crossref_primary_10_1161_JAHA_117_006986 crossref_primary_10_15829_1560_4071_2024_6117 crossref_primary_10_1111_jch_14740 crossref_primary_10_15829_1560_4071_2020_3_3782 crossref_primary_10_1161_HYPERTENSIONAHA_124_23385 crossref_primary_10_1136_postgradmedj_2020_139701 crossref_primary_10_1038_s41371_018_0036_3 crossref_primary_10_1038_s41598_024_67261_w crossref_primary_10_1097_HJH_0000000000003436 crossref_primary_10_18087_cardio_2019_12_n547 crossref_primary_10_1177_1470320317710891 crossref_primary_10_1007_s11606_020_05731_3 crossref_primary_10_1002_pdi_2389 crossref_primary_10_1177_1470320320975893 crossref_primary_10_1038_s41467_019_09186_x crossref_primary_10_1161_HYPERTENSIONAHA_116_07433 crossref_primary_10_1681_ASN_2019090905 crossref_primary_10_1097_HJH_0000000000003480 crossref_primary_10_1016_j_jash_2016_05_013 crossref_primary_10_1530_EDM_16_0013 crossref_primary_10_1097_HJH_0000000000002453 crossref_primary_10_1093_eurheartj_ehy339 crossref_primary_10_1007_s15027_024_3715_8 crossref_primary_10_1007_s11906_016_0641_x crossref_primary_10_1161_JAHA_120_016387 crossref_primary_10_1371_journal_pone_0208892 crossref_primary_10_1016_j_ahj_2024_07_006 crossref_primary_10_1007_s11892_018_0976_6 crossref_primary_10_3389_fphys_2016_00320 crossref_primary_10_3389_fphar_2025_1513125 crossref_primary_10_1002_clc_22528 crossref_primary_10_1038_s41391_020_0220_8 crossref_primary_10_1093_ajh_hpad118 crossref_primary_10_1016_j_lfs_2024_122853 crossref_primary_10_1097_HJH_0000000000002088 crossref_primary_10_1016_S2213_8587_18_30071_8 crossref_primary_10_1111_jch_14705 crossref_primary_10_3390_cells10061285 crossref_primary_10_1161_JAHA_117_007760 crossref_primary_10_1186_s13063_025_08719_8 crossref_primary_10_1093_eurheartj_ehv721 crossref_primary_10_1089_met_2019_0099 crossref_primary_10_2174_1381612829666230331093912 crossref_primary_10_1007_s11906_021_01151_8 crossref_primary_10_1002_jbm4_10683 crossref_primary_10_1097_MNH_0000000000000578 |
| ContentType | Journal Article |
| Contributor | Helmy, Jo Quinn, Ursula Thom, Simon A McG Hobbs, Richard Palmer, Jo Rutkowski, Krzysztof Myint, Khin Swe Coughlan, Candida MacIntyre, Iain M Kwok, See Iles, Rachel Collier, David Schumann, Anne Balakrishnan, Karthirani Papworth, Richard Markandu, Nirmala Findlay, Evelyn Harrow, Craig Cannon, John Woods, Sarah Mackay, Judith Stanley, Adrian G Soran, Handrean Webb, Andrew Hood, Sue Kean, Sharon Maniero, Carmela Maxwell, Simon Martin, Una White, Christobelle McCallum, Linsay Lacey, Peter Zak, Anne Burton, Timothy J Taylor, Clare Bartlett, Carole McInnes, Gordon T Saxena, Manish Patterson, Caroline Melville, Vanessa Turtle, Emma Wilson, Robbie Gardiner-Hill, Caroline J McGinnis, Alison R Padmanabhan, Sandosh Brown, Roger Hobbs, Lorraine |
| Contributor_xml | – sequence: 1 givenname: Anne surname: Schumann fullname: Schumann, Anne – sequence: 2 givenname: Jo surname: Helmy fullname: Helmy, Jo – sequence: 3 givenname: Carmela surname: Maniero fullname: Maniero, Carmela – sequence: 4 givenname: Timothy J surname: Burton fullname: Burton, Timothy J – sequence: 5 givenname: Ursula surname: Quinn fullname: Quinn, Ursula – sequence: 6 givenname: Lorraine surname: Hobbs fullname: Hobbs, Lorraine – sequence: 7 givenname: Sarah surname: Woods fullname: Woods, Sarah – sequence: 8 givenname: Carole surname: Bartlett fullname: Bartlett, Carole – sequence: 9 givenname: Jo surname: Palmer fullname: Palmer, Jo – sequence: 10 givenname: David surname: Collier fullname: Collier, David – sequence: 11 givenname: Nirmala surname: Markandu fullname: Markandu, Nirmala – sequence: 12 givenname: Manish surname: Saxena fullname: Saxena, Manish – sequence: 13 givenname: Anne surname: Zak fullname: Zak, Anne – sequence: 14 givenname: Judith surname: Mackay fullname: Mackay, Judith – sequence: 15 givenname: Simon A McG surname: Thom fullname: Thom, Simon A McG – sequence: 16 givenname: Candida surname: Coughlan fullname: Coughlan, Candida – sequence: 17 givenname: Alison R surname: McGinnis fullname: McGinnis, Alison R – sequence: 18 givenname: Evelyn surname: Findlay fullname: Findlay, Evelyn – sequence: 19 givenname: Caroline surname: Patterson fullname: Patterson, Caroline – sequence: 20 givenname: Adrian G surname: Stanley fullname: Stanley, Adrian G – sequence: 21 givenname: Christobelle surname: White fullname: White, Christobelle – sequence: 22 givenname: Peter surname: Lacey fullname: Lacey, Peter – sequence: 23 givenname: Caroline J surname: Gardiner-Hill fullname: Gardiner-Hill, Caroline J – sequence: 24 givenname: Sandosh surname: Padmanabhan fullname: Padmanabhan, Sandosh – sequence: 25 givenname: Gordon T surname: McInnes fullname: McInnes, Gordon T – sequence: 26 givenname: Craig surname: Harrow fullname: Harrow, Craig – sequence: 27 givenname: Linsay surname: McCallum fullname: McCallum, Linsay – sequence: 28 givenname: Vanessa surname: Melville fullname: Melville, Vanessa – sequence: 29 givenname: Iain M surname: MacIntyre fullname: MacIntyre, Iain M – sequence: 30 givenname: Emma surname: Turtle fullname: Turtle, Emma – sequence: 31 givenname: Roger surname: Brown fullname: Brown, Roger – sequence: 32 givenname: Simon surname: Maxwell fullname: Maxwell, Simon – sequence: 33 givenname: Handrean surname: Soran fullname: Soran, Handrean – sequence: 34 givenname: See surname: Kwok fullname: Kwok, See – sequence: 35 givenname: Karthirani surname: Balakrishnan fullname: Balakrishnan, Karthirani – sequence: 36 givenname: Richard surname: Hobbs fullname: Hobbs, Richard – sequence: 37 givenname: Rachel surname: Iles fullname: Iles, Rachel – sequence: 38 givenname: Clare surname: Taylor fullname: Taylor, Clare – sequence: 39 givenname: Khin Swe surname: Myint fullname: Myint, Khin Swe – sequence: 40 givenname: John surname: Cannon fullname: Cannon, John – sequence: 41 givenname: Sue surname: Hood fullname: Hood, Sue – sequence: 42 givenname: Andrew surname: Webb fullname: Webb, Andrew – sequence: 43 givenname: Krzysztof surname: Rutkowski fullname: Rutkowski, Krzysztof – sequence: 44 givenname: Una surname: Martin fullname: Martin, Una – sequence: 45 givenname: Sharon surname: Kean fullname: Kean, Sharon – sequence: 46 givenname: Robbie surname: Wilson fullname: Wilson, Robbie – sequence: 47 givenname: Richard surname: Papworth fullname: Papworth, Richard |
| Copyright | Copyright © 2016 Brown et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2016 Brown et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. |
| CorporateAuthor | British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group |
| CorporateAuthor_xml | – name: British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S2213-8587(15)00377-0 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2213-8595 |
| ExternalDocumentID | 26489809 |
| Genre | Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase IV |
| GrantInformation | British Heart Foundation and National Institute for Health Research. |
| GrantInformation_xml | – fundername: Department of Health – fundername: British Heart Foundation grantid: PG/07/085/23349 – fundername: British Heart Foundation grantid: SP/08/002 – fundername: British Heart Foundation grantid: FS/14/12/30540 – fundername: Medical Research Council grantid: MC_PC_13090 – fundername: British Heart Foundation grantid: FS/11/35/28871 – fundername: British Heart Foundation grantid: FS/14/75/31134 – fundername: Medical Research Council grantid: MR/K006584/1 – fundername: British Heart Foundation grantid: SP/08/002/24118 – fundername: Medical Research Council grantid: G9521010 |
| GroupedDBID | -RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAQQT AAXUO ABUDA ACGFS ADBBV AENEX AFRHN AFTJW AGCQF AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CGR CUY CVF EBS ECM EIF EJD FDB GBLVA HZ~ NPM O9- OB0 ON- ROL Z5R 7X8 ACVFH ADCNI EFKBS |
| ID | FETCH-LOGICAL-c646t-245d17d6791ee4e543b096dae229615c073449141e49e3acdd7cb27cef59a8e42 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 72 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000368705000025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2213-8595 |
| IngestDate | Sun Sep 28 08:58:37 EDT 2025 Sat May 31 02:05:00 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | Copyright © 2016 Brown et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c646t-245d17d6791ee4e543b096dae229615c073449141e49e3acdd7cb27cef59a8e42 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4728199 |
| PMID | 26489809 |
| PQID | 1761471999 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1761471999 pubmed_primary_26489809 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-02-01 |
| PublicationDateYYYYMMDD | 2016-02-01 |
| PublicationDate_xml | – month: 02 year: 2016 text: 2016-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The lancet. Diabetes & endocrinology |
| PublicationTitleAlternate | Lancet Diabetes Endocrinol |
| PublicationYear | 2016 |
| References | 26489807 - Lancet Diabetes Endocrinol. 2016 Feb;4(2):90-2. doi: 10.1016/S2213-8587(15)00391-5. |
| References_xml | – reference: 26489807 - Lancet Diabetes Endocrinol. 2016 Feb;4(2):90-2. doi: 10.1016/S2213-8587(15)00391-5. |
| SSID | ssj0001053680 |
| Score | 2.4177845 |
| Snippet | Potassium depletion by thiazide diuretics is associated with a rise in blood glucose. We assessed whether addition or substitution of a potassium-sparing... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 136 |
| SubjectTerms | Aged Amiloride - therapeutic use Diuretics - therapeutic use Double-Blind Method Female Glucose Intolerance - chemically induced Glucose Intolerance - prevention & control Humans Hydrochlorothiazide - adverse effects Hypertension - drug therapy Male Middle Aged |
| Title | Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26489809 https://www.proquest.com/docview/1761471999 |
| Volume | 4 |
| WOSCitedRecordID | wos000368705000025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZtUkovfadNX0yhhwQiYsmyZfUSltKQS5aFpnR7WvQYk4CxtvsotH8vfywjrcNeWij0YvBDQjDj0afRp_kY-9C4wgufaIM0V3JVGcdd7TS3pg5If19Sd8hiE3o8bqZTMxkSbsuBVnkbE3OgDtGnHPmxoPU2BVLCMyfzHzypRqXd1UFC4y7bLQnKJK_W02abYyEPq7N4mpSi5KmU1_YQz_GX4WGjD0R1mAqxaF78HWjmCef00f8O9TF7OEBNGG184wm7g_1Tdv982Ex_xq43lYshtpCyHNRDwCOIi-0dzLv1Ei5_haSrRY_Iqlf2d_4ssTn-_A5iDwMRHlaxw6TcgWD7AJkkD5l5u14gHExGF2ffRt95efgRLKQi5F2HHc8HTY4gxLXrkDvCwQGokxDJJZHaX9LECwqy3shz9vX088WnMz5oOnBfq3rFpaqC0KHWRiAqrFTpaBEVLEppCFx5ijhKGaEEKoOl9SFo76T22FbGNqjkHtvpY48vGaBqCqSI5AtJzua8w6q1BKiEtlWQbbnP3t-aZ0YDTBshtse4Xs62BtpnLzY2ns03xT1mifFnmsK8-ofWr9kDwk8DifsN220pYuBbds__XF0tF--yM9J1PDm_AbL06ug |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+amiloride%2C+or+amiloride+plus+hydrochlorothiazide%2C+versus+hydrochlorothiazide+on+glucose+tolerance+and+blood+pressure+%28PATHWAY-3%29%3A+a+parallel-group%2C+double-blind+randomised+phase+4+trial&rft.jtitle=The+lancet.+Diabetes+%26+endocrinology&rft.au=Brown%2C+Morris+J&rft.au=Williams%2C+Bryan&rft.au=Morant%2C+Steve+V&rft.au=Webb%2C+David+J&rft.date=2016-02-01&rft.issn=2213-8595&rft.eissn=2213-8595&rft.volume=4&rft.issue=2&rft.spage=136&rft_id=info:doi/10.1016%2FS2213-8587%2815%2900377-0&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-8595&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-8595&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-8595&client=summon |